Johnson & Johnson (NYSE:JNJ) Shares Purchased by Drystone LLC

Drystone LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,745 shares of the company's stock after acquiring an additional 1,739 shares during the quarter. Johnson & Johnson comprises approximately 3.6% of Drystone LLC's portfolio, making the stock its 14th biggest position. Drystone LLC's holdings in Johnson & Johnson were worth $3,606,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC lifted its holdings in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the period. Proficio Capital Partners LLC grew its position in Johnson & Johnson by 22.0% in the 4th quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock valued at $2,885,000 after buying an additional 3,594 shares during the last quarter. one8zero8 LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $9,930,000. Finally, Pollock Investment Advisors LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $1,040,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ traded up $0.01 during midday trading on Monday, reaching $156.91. 10,184,400 shares of the company's stock were exchanged, compared to its average volume of 9,032,256. The business's 50-day moving average price is $153.75 and its 200 day moving average price is $154.55. The stock has a market capitalization of $377.55 billion, a PE ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Raymond James Financial lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Barclays dropped their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.